1.
|
Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: RRK4368, 2012-002552-16, NCT01668459
|
|
2.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: VRAM M-20070240, NCT00647569
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-90601, CALGB-90601, NCT00942331
|
|
4.
|
Phase: Phase III Type: Educational/Counseling/Training, Supportive care Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UHN REB 09-0855-C, CIHR, NCT01506492
|
|
5.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000492014, U01CA062505, CCC-PHII-75, NCI-7435, 7435, NCT00365157
|
|
6.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: WCTU-TOTEM, WCTU-TOTEM, ISRCTN31546330, EUDRACT-2007-007615-82, EU-21014, WCTU-SPON-417-07, CRUK-08/015, NCT01090466
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AEZS-108-046, EProst # 20091095, NCT01234519
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DZITM1, NCT01265940
|
|
9.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
|
|
10.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CA-ALT-801-01-10, NCT01326871
|
|
11.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-1339, NCT01342172
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0609001823, NCT00461851
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: IOSI-RO0402, RO0402, NCT00637637
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ABX207-GU07CA, NCT00683059
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-0933, NCT00756639
|
|
16.
|
Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ITA-MIL-IRCCS-INT-70/09, IRCCS-INT 70/09, EUDRACT-2009-017093-20, EU-20990, NCT01031875
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FER-GU-026, NCT01031420
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: CDR0000667764, WCTU-SUCCINCT, ISRCTN54607216, EUDRACT-2007-007591-42, EU-21013, WCTU-SPON-416-07, CRUK-07/044, NCT01089088
|
|
19.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: HDM-SU-011248, SU- 011248, EUDRACT-2005-005115-16, PFIZER-HDM-SU-011248, NCT01118039
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BLDR0010, SU-04152010-5683, NCT01108055
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000684016, WCTU-TOUCAN, ISRCTN-68146831, EUDRACT-2009-010140-33, EU-21066, CRUK-09/024, WCTU-SPON-672-09, ZENECA-WCTU-TOUCAN, NCT01191892
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HOG GU10-147, NCT01215136
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOBL204, NCT01215877
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-208, NCT01261728
|
|
25.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13943, CP20-0902, I4Y-IE-JCDC, NCT01282463
|